fibrosis [5] . Over the next 25 years there is almost a linear decrease in the proportion of surgery-free patients as seen in figure 1 .
Whereas we are able to control for inflammation better and better, an effective preventive therapy for fibrosis or a pharmacological approach that even could reduce fibrosis is virtually absent. Most gastroenterologists believe that surgery can be avoided by preventing or reducing inflammation. This concept has also been brought forward by Pariente et al. [6] . In this concept, surgery occurs upon a chronic subclinical inflammation and subsequent fibrosis [6] . The evidence, however, to support this concept is weak. To some extent fibrosis might be independent from the inflammatory process. We find fibrotic strictures also in patients fibrotic strictures also in patients without IBD at surgical anastomosis, indicating that fibrosis might occur completely without any basic inflammation.
It is obvious that fibrosis research and development of potential therapeutic avenues is much more advanced in other fibrotic diseases when compared to IBD. Therefore, it is important to think 'out of the box' and to learn from those areas to improve the situation of patients with CD or ulcerative colitis. Whereas there is some progress in basic research on fibrosis in IBD, clinical research and fibrosis therapy is still virtually absent. An indicator for the interest in fibrosis certainly is that the 4th Scientific Workshop of the European Crohn's and Colitis Foundation (ECCO) was focused on the subject of fibrosis in CD. A series of review articles have recently been published on the subject, featuring pathogenesis, markers and potential treatment [7, 8] .
Which Therapeutic Targets Have Been Identified in Other Fibrotic Diseases?
Basic research in liver fibrosis not only focuses on the anti-inflammatory agents and the reduction of injury as is usually done in CD [9] [10] [11] [12] . Several other fields of interest have been introduced in liver fibrosis research. Inhibitors of proliferation and angiogenesis have been shown to be successful in prevention of liver fibrosis. An example is the Hedgehog signaling pathway. It is a signaling pathway identified to transmit information to embryonic cells required for proper development. An involvement of this factor or pathway has recently been discussed also for idiopathic pulmonary fibrosis and other fibrotic diseases [13, 14] . The Hedgehog pathway was found to be activated in lungs of patients with idiopathic pulmonary fibrosis, thereby contributing to idiopathic pulmonary fibrosis pathogenesis by increasing the proliferation, migration, extracellular matrix production and survival of pulmonary fibroblasts [13] .
Fibrogenesis inhibitors also have been tested in animal models of fibrotic disease. Among those direct fibrogenesis inhibitors are TGF-β1 and TGF-β1 receptor antagonists [15] [16] [17] [18] [19] , hepatocyte growth factor agonist [20] , angiotensin-receptor antagonists [21, 22] , ACE inhibitors [23] , connective tissue growth factor antagonists [24, 25] , cannabinoid receptor 1 antagonist [26] [27] [28] and lysophosphatidic acid receptor type 1 antagonists [29, 30] . In addition to direct fibrogenesis inhibitors, enhanced degradation of extracellular matrix proteins has proven to be promising in a number of experimental models [31, 32] . Fig. 1 . Proportion of surgery-free patients in the Swiss IBD cohort study over time (according to [5] 41 Tested substances in those models were tissue inhibitors of metalloproteinases [33] , TGF-β antagonists, cell modulation therapy and inhibitors of lysyl oxidase-like 2 (LOXL2) [34] . The LOX enzyme also plays an important role in therapeutic trials in lung fibrosis. Therefore, this interesting molecule that is not studied in CD could be of future interest. Lysyl oxidase-like (LOX) refers to a group of copper-dependent amine oxidases that catalyze the covalent cross-link of collagens and elastin in the extracellular environment [35] . LOXL2 as a prototypic member of the group plays an essential role in the formation of connective tissue. It thus influences the mechanical properties of the extracellular matrix [35] . A dysregulation of LOXL2 has been discussed to play an important role in the pathogenesis of fibrosis in different organs.
Why Is Fibrosis Research in IBD Not More Advanced?
Fibrosis research, especially with respect to the development of therapeutic targets, is hampered by two major problems. While there are some models of intestinal fibrosis available, they all have certain disadvantages. Animal models of fibrosis have been recently summarized and reviewed by Pizarro and colleagues [36, 37] . In most of the animal models, fibrosis is either induced by chemicals such as dextran sodium sulfate [38] [39] [40] or 2,4,6-trinitrobenzenesulfonic acid [41] [42] [43] [44] [45] [46] [47] [48] , or by bacterial cell wall products such as peptidoglycan [49, 50] .
Only one spontaneous model, the SAMP1/YitFc mouse strain, which develops CD-like ileitis, has been studied in detail by Pizarro and colleagues [37, 51] . Certainly this mouse model has the great advantage that intestinal fibrosis indeed develops spontaneously without any chemical induction that may not reflect natural pathophysiology and that there is additional inflammation in the terminal ileum similar to what is seen in humans. On the other hand, the model is not very stable and seems to depend to some extent on the bacterial flora [52] . Also, fibrosis in the chemically induced models is variable and only occurs after a long time. Therefore, for the study of intestinal fibrosis, new models would be highly warranted that develop fibrosis rapidly and reliably to a constant extent.
To develop such a model of intestinal fibrosis with the advantages mentioned above, we adapted a heterotopic tracheal transplant model that was developed a long time ago for the investigation of bronchiolitis obliterans (BO) after lung transplantation [53, 54] . BO also occurs after allogeneic stem cell transplantation. Single nucleotide polymorphisms that are relevant susceptibility factors in the pathogenesis of CD such as NOD2 were also shown to contribute to the risk of developing BO [55] .
To study therapeutic prevention of BO, a piece of trachea was transplanted heterotopically into the neck fold of rats where it developed fibrosis with a constant time course [53, 54] . We adopted this rat model and transplanted small parts of the small intestine also in the neck fold of isogenic animals [56] . Donor (Brown Norway or Lewis rats) small bowel resections were transplanted subcutaneously into the neck of recipients (Lewis rats) [56] . Grafts were explanted 2, 7, 14 and 21 days after transplantation. The neck fold was chosen because the animals are unable to scratch themselves there, avoiding mechanical irritation that can influence the development of fibrosis. Rapid fibrosis occurred similar to the BO model. Collagen expression was increased with time [56] . Lumen obliteration was associated with increased expression of fibrosis-mediators such as α V β 6 integrin, IL-13 and TGF-β [56] . Several typical histologic and molecular features of intestinal fibrosis were observed in this heterotopic intestinal graft model. Within 3 weeks there was an almost tenfold increase in fibrotic layer thickness. This indicates that there is indeed rapid and stable fibrosis development. mRNA expression of collagen-1 was increased 100-fold after 3 weeks as compared to baseline [56] . This model may to some extend solve the problem of a lack of a rapid and reliable model of intestinal fibrosis. It will be possible to study and screen a number of agents on their ability to prevent intestinal fibrosis, thus identifying promising drug candidates for the prevention/treatment of intestinal fibrosis.
Why Do We Have No Clinical Trials on the Prevention of Intestinal Fibrosis?
There is a second aspect that prevents the development of successful therapies for CD fibrosis: the lack of a reliable endpoint for clinical trials. So far we do not have any reliable biomarker that would fulfill the criteria for a good endpoint in a respective clinical study. There are no reliable serum markers of intestinal fibrosis that would nicely correlate with the process of fibrosis or the degree of collagen deposition. YKL-40 has been reported to be a marker for liver fibrosis [57] . It is also increased when intestinal strictures are present, but the correlation coefficient is only r = 0.457 and serum levels are also increased during active inflammation [58] making this marker not a good candidate for a surrogate marker in clinical trials.
All of the other 'marker-candidates' studied so far have not proven a sufficient correlation with the degree of intestinal fibrosis to be useful for monitoring antifibrotic therapy. It could be that the volume of the fibrotic area is too small in intestinal fibrosis to be represented reliably by a serum marker.
On the other hand, imaging techniques have not been developed to a state where they can be used as clinical endpoints. In CT scans or MRI as well as ultrasound, the evaluation of fibrosis mostly relies on subjective parameters. Contrast enhancement is usually seen as a sign of inflammation. However, active fibrosis could also lead to contrast enhancement because it is a biologically and metabolically highly active process. Only when fibrosis is already established and a full scar or sclerosis has developed is contrast enhancement no longer seen. A recently developed technique developed for the detection of intestinal fibrosis in MRI is 'magnetization transfer' [49, 50] . MR magnetization transfer imaging has several advantages as compared to conventional MRI. Magnetization transfer generates contrast that is primarily determined by the fraction of large macromolecules or immobilized phospholipid cell membranes in tissue [50] . This means that bone, cartilage and muscle will also show a high signal in magnetization transfer. Nevertheless, it is possible to identify fibrotic strictures in the gut. In a recent study in normal nonfibrotic bowel wall segments, an intermediate magnetization transfer ratio of 25.4 ± 3.4% was measured [59] . In contrast, the magnetization transfer ratio was significantly increased in bowel wall segments with fibrotic areas (35.3 ± 4.0%, p < 0.0001) [59] . In bowel segments with acute inflammation and no fibrosis, the mean magnetization transfer ratio was slightly lower than in the normal bowel wall without reaching a level of significance (22.9 ± 2.2%). As is obvious from the above numbers, it is possible to quantify magnetization transfer and give a ratio to have a quantification of tissue fibrosis. If magnetization transfer in MRI is further developed, this may be a promising technique to quantify intestinal fibrosis and to provide a quantitative endpoint for clinical trials on intestinal fibrosis. Currently, a large trial has been initiated in Europe that will investigate the usefulness of magnetization transfer as an endpoint for clinical trials of intestinal fibrosis. On the other hand, new ultrasound techniques and FibroScan ® may be promising [60] [61] [62] [63] [64] . New developments have taken place that could allow quantification of fibrosis with ultrasound in the near future.
Which Endpoints Are Used in Clinical Trials on Fibrosis in Clinical Trials on Fibrosis in Other Diseases?
As mentioned earlier, the lack of a clinical endpoint is a major disadvantage for trials on intestinal fibrosis. So, why are there reliable endpoints in other diseases and what are those endpoints? FibroScan is used for liver fibrosis, but the method so far is not perfectly reproducible [65] . On the other hand, liver biopsy is frequently seen as the gold standard, but has the disadvantage of a patchy distribution of fibrosis in many patients. Results might be hampered by this fact and therefore patient numbers included in those studies must be rather high to avoid a bias by the patchiness of the tissue sample.
In contrast, there is a very reliable endpoint for clinical trials in idiopathic pulmonary fibrosis. This is the reason why most clinical fibrosis trials are done in this indication. The endpoint in all those trials is the 'forced vital capacity' [66] . The vital capacity is the maximum amount of air a person can expel from the lungs after maximum inhalation. A patient's vital capacity of course can easily be measured by a spirometer in a regular setting. This endpoint for clinical trials can be measured without any invasive methods, can be easily repeated, and is not of any disadvantage or risk for the patient [66] . Therefore, idiopathic pulmonary fibrosis is the main indication of the development of antifibrotic drugs for many pharmaceutical companies despite the fact that the number of patients with idiopathic pulmonary fibrosis is much lower as compared to patients with intestinal fibrosis due to CD.
The factors that have been identified to play a role in the pathogenesis of idiopathic pulmonary fibrosis are similar to those identified to be relevant during intestinal fibrosis. Data show that growth factors such as plateletderived growth factor (PDGF), epidermal growth factor, TGF-α and -β, or endothelin-1 play an important role in promoting intestinal fibrosis and deposition of collagen [67] [68] [69] [70] . Prostaglandin E 2 seems to inhibit pulmonary fibrosis [71, 72] . IL-4, IL-13, fibroblast growth factor, insulin-like growth factor and cytokines such as IL-1 are also profibrogenic [73] [74] [75] . In principal all of those mediators also play a role in intestinal fibrosis, indicating that a fibrotic stimulus is probably locally active and that the mechanisms are very similar in lung and intestinal fibrosis. This indicates that results derived from animal studies and clinical trials in idiopathic pulmonary fibrosis may be transferable to intestinal fibrosis, which calls for more scientific interaction between pulmonologists and gastroenterologists. 
Clinical Trials in Idiopathic Pulmonary Fibrosis
Despite the prototypic role of idiopathic lung fibrosis for fibrotic disease and the above-mentioned clear clinical endpoint, so far only one substance is approved for the treatment of idiopathic pulmonary fibrosis and one has an orphan drug status.
The only currently approved drug for lung fibrosis is pirfenidone [76] [77] [78] [79] . It is an orally active, small molecule that inhibits the synthesis of profibrotic and inflammatory mediators. Chemically, pirfenidone is 5-methyl-1-phenylpyridin-2-one [80] . The precise mechanism of action of pirfenidone is still unknown. Pirfenidone has several effects that can be interpreted as being 'antifibrotic'. Among others, it reduces the expression of collagen in fibroblast and muscle cells in vitro [80] . In 2 out of 3 phase 3 trials, pirfenidone significantly reduced the decline of the forced vital capacity in patients with idiopathic pulmonary fibrosis [76, 81] . This finally led to approval by the FDA. Recently another phase 3 trial on pirfenidone was published in The New England Journal of Medicine [77] (in the same issue where the study on nintedanib was published). This phase 3 trial studied 555 patients with idiopathic pulmonary fibrosis who were assigned to receive either oral pirfenidone (2,403 mg/day) or placebo over a period of 52 weeks [77] . The primary endpoint of this trial was again the change in forced vital capacity or death at week 52. In the pirfenidone group, a relative reduction of 47.9% in the proportion of patients who had an absolute decline of 10% or more in the percentage of the predicted forced vital capacity or who died was observed [77] . Thus, the whole trial achieved significance and confirmed that pirfenidone successfully prevents progress of idiopathic pulmonary fibrosis [77] . Unfortunately, gastrointestinal and skin-related adverse events were more common in the pirfenidone group than in the placebo group. Pain and diarrhea were among the gastrointestinal side effects. This might limit the acceptability of pirfenidone for the treatment of CD patients [77] . In May 2014 an also large trial on the efficacy and safety of nintedanib (BIBF1120) in idiopathic pulmonary fibrosis was published in The New England Journal of Medicine [82] ( table 1 ) . Nintedanib is an intracellular tyrosine kinase inhibitor. INPULSIS-1 and INPULSIS-2 were two replicate 22-week, randomized, double-blind, phase 3 trials in altogether 1,066 patients [82] . The primary endpoint was (not surprisingly) the reduction in the annual rate of decline in forced vital capacity. Both trials reached their endpoints with high significance. In INPULSIS-1 the annual rate of changed enforced vital capacity was -114.7 ml with nintedanib versus -239.9 ml in the placebo group (Δ125.3 ml, p < 0.001) [82] . In INPULSIS-2 the patients treated with nintedanib lost 113.6 ml of their forced vital capacity over the 12-month trial period, whereas the placebo-treated patients lost 207.3 ml of their forced vital capacity (Δ93.7 ml, p < 0.001) [82] . It is striking that in those two studies the effect of the drug was so similar. Obviously, this tyrosine kinase inhibitor effectively reduces the progress of pulmonary fibrosis. However, application in intestinal fibrosis may be hampered by the most important side effect reported in those two trials: the most frequent adverse event in the nintedanib groups was diarrhea which occurred in 61.5% of the patients in INPULSIS-1 and in 63.2% in INPULSIS-2 [82] . It caused therapy to be discontinued in a significant number of patients. As is obvious, CD patients would be even more affected by an induction of diarrhea by the study drug.
However, it might be possible to use lower dosages of nintedanib in patients with CD fibrosis. The dosage for idiopathic pulmonary fibrosis has been determined in earlier studies such as the TOMORROW trial [83, 84] . In the TOMORROW trial, dosages of nintedanib (BIBF1120) less than 150 mg twice daily, however, were not effective [84] . 50 mg once daily, 50 mg twice daily or 100 mg twice daily were not significantly different to placebo with respect to the annual rate of change in forced vital capacity as published by Woodcock et al. [84] .
With respect to the pathophysiological targets, nintedanib could also work in intestinal fibrosis. It dose-dependently inhibits the phosphorylation of several receptors of growth factors such as the phosphorylation of PDGF receptor by PDGF-BB as shown by Wollin et al. [85] . As PDGF also plays a role in intestinal fibrosis, this pathway could well be effective.
A number of different antibodies and compounds are being tested at present for the indication of idiopathic pulmonary fibrosis ( table 1 ) : Centocore is performing a phase 2 trial on the safety and effectiveness of CNTO 888 compared to placebo (NCT00786201). CNTO 888 is also named carlumab and is a human monoclonal antibody against the chemokine (C-C motif) ligand 2, which has earlier been referred to as monocyte chemotactic protein 1, which is known to recruit monocytes, activated and memory T cells, and dendritic cells to the sites of inflammation [86] [87] [88] . A role for monocyte chemotactic protein 1 has already been shown in intestinal inflammation and fibroblast activation [89] [90] [91] .
Another phase 2 trial studied the effect of lebrikizumab in patients with idiopathic pulmonary fibrosis (NCT01872689). Lebrikizumab is an anti-IL-13 antibody manufactured by Hoffmann-La Roche. IL-13 also has been associated with intestinal fibrosis and is generally believed to be a profibrotic cytokine [92] [93] [94] [95] .
Another interesting drug that is being studied in the area of idiopathic pulmonary fibrosis is simtuzumab (GS-6624; formerly AB0024). A phase 1 study was completed and a phase 2 study is active (NCT01362231; NCT01769196). This antibody targets the above-mentioned LOXL2. The trials are being performed by Gilead Sciences, and the phase 1 and 2 trials seem to be promising.
MedImmune is conducting a phase 2 trial in idiopathic pulmonary fibrosis which is a randomized, dose-ranged study to evaluate the efficacy of tralokinumab in adults. Tralokinumab is a human recombinant monoclonal antibody that specifically binds human IL-13.
A list of published clinical trials in pulmonary fibrosis can be seen in table 2 [96] . It shows that endothelin receptor antagonists have been studied with some success and that at the moment tyrosine kinase inhibitors and pirfenidone have demonstrated the most promising results [96] . On the other hand, IFN-γ has been studied in investigator-initiated trials [97, 98] . It is an attractive therapeutic candidate as it regulates both macrophages and fibroblast functions. IFN-γ inhibits fibrogenic growth factors (FGFs), namely FGF2 and basic FGF, and a variety of neutrophil-derived cytokines.
Other substances also have shown some effects in models of pulmonary fibrosis. Suramin is a sulfonated naphthyl-urea that antagonizes the effects of certain growth factors including TGF-β, insulin-like growth factor-1, PDGF and FGF. On the other hand -as most TGF-β antagonists -it delays wound healing which could 45 be deleterious in CD. Relaxin is another factor studied in the field of lung fibrosis. Relaxin inhibits TGF-β-induced collagen and fibronectin synthesis by fibroblasts, and increases the expression of matrix metalloproteinase 1, which is able to degrade collagen.
Clinical Trials in Other Fibrotic Diseases
A number of clinical trials also have been finished or are currently ongoing in liver fibrosis ( 46 targets LOXL2, is also being studied in liver fibrosis in subjects with advanced liver fibrosis, but not cirrhosis secondary to NASH. Two phase 2 trials are registered. The results have not been published yet. FibroGen is studying FG-3019 in subjects with liver fibrosis due to chronic hepatitis B infection. FG-3019 is a human monoclonal antibody against connective tissue growth factor. The drug has been granted orphan drug designation by the FDA for the treatment of idiopathic pulmonary fibrosis due to promising data from a clinical trial there.
Conclusion
As is obvious from the clinical trials mentioned above, antifibrotic treatments are mainly studied in idiopathic pulmonary fibrosis and to a lesser extent in hepatic fibrosis, whereas there are almost no trials ongoing in intestinal fibrosis. This is mainly due to two factors. First, we do not have animal models of intestinal fibrosis that are reliable and develop fibrosis fast enough to do a number of screening experiments. Even more importantly, intestinal fibrosis is hard to assess and there are no reliable endpoints for clinical trials. Magnetization transfer and new ultrasound techniques may provide us with these endpoints; however, they need financial support to be further developed in the near future. At present a new Europeanwide clinical trial has been started to validate MRI for the assessment of intestinal fibrosis.
We should also join in efforts to develop new animal models for intestinal fibrosis. Therapies successful in pulmonary fibrosis should now be studied in intestinal fibrosis. The models available so far may be a starting point.
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